ALK POSITIVE
Cart 0
Home ALKtALK Shop
Join
Research Grants ALK Research Library Cutting Edge Trials Clinical Trials ALK Life Study
Get Support What is ALK Treatment & Resources 2nd Opinion Program ALK Summit 2024
About Us Finances Alliances Contact Press
Blog Newsletters Prospectus Annual Report
Donate Ways to Give Fundraise with ALK+
Cart 0
Home Research Research Grants ALK Research Library Cutting Edge Trials Clinical Trials ALK Life Study Patients Get Support What is ALK Treatment & Resources 2nd Opinion Program ALK Summit 2024 About About Us Finances Alliances Contact Press ALKtALK Media Blog Newsletters Prospectus Annual Report Shop
ALK POSITIVE
Donate Donate Ways to Give Fundraise with ALK+ Join
ALKtALK: Dr. Dagogo-Jack and Dr. Jessica Lin

Dr. Jessica Lin and Dr. Ibiayi Dagogo-Jack explain their new clinical trial combining Lorlatinib with a SHIP2 inhibitor, TN0155 to the ALK Positive patient group. WATCH VIDEO

ALK Positive Inc.

Authors: Jessica Lin, Ibiayi Dagogo-Jack

VideoKirk SmithMarch 1, 2021ALKtALK
Facebook0 Twitter LinkedIn0 0 Likes
Previous

ALKtALK: Dr. Mark Awad and Dr. Roberto Chiarle at ALKtALK

VideoKirk SmithMarch 1, 2021ALKtALK
Next

ALKtALK: Dr. Justin Gainor and Dr. Aaron Hata

VideoKirk SmithMarch 1, 2021ALKtALK
Donate
Join Support Group

info@alkpositive.org

ALK Positive, Inc. 6595 Roswell Road;

Suite G2310 Atlanta, GA 30328

Please send checks to:

ALK LOCKBOX, P.O. Box 24960 New York, New York 10087-4960

Subscribe

Sign up with your email address to receive news and updates.

We respect your privacy.

Thank you!
info@alkpositive.org
Hours
Mon Open
Tue Open
Wed Open
Thu Open
Fri Open
Sat Open
Sun Open
Log InPressHomeLinksContact UsBlogPrivacy Policy

The content on the ALK Positive website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.  © ALK Positive, Inc. All Rights Reserved